(Q36150866)

12 August 2017

1 reference

title

Targeting signalling pathways for the treatment of multiple myeloma (English)

1 reference

12 August 2017

4

Kenneth C Anderson

1 reference

12 August 2017

Klaus Podar

1

1 reference

12 August 2017

Teru Hideshima

series ordinal

2

1 reference

12 August 2017

Dharminder Chauhan

series ordinal

3

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 April 2005

1 reference

Expert Opinion on Therapeutic Targets

12 August 2017

1 reference

12 August 2017

9

1 reference

12 August 2017

2

1 reference

12 August 2017

359-381

1 reference

Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly

12 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Erythropoietin treatment of anemia associated with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

New drugs for treatment of multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Multiple myeloma: evolving genetic events and host interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Chromosome translocations in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Advances in biology of multiple myeloma: clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Clinical and biologic implications of recurrent genomic aberrations in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopic p18 expression inhibits growth and induces apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Identification of a functionally impaired positive regulatory domain I binding factor 1 transcription repressor in myeloma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Connecting chromosomes, crisis, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Telomerase inhibitors as anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Macrophage inflammatory protein 1-alpha (MIP-1 alpha ) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

C-kit ligand (SCF) in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Expression and functional role of c-kit ligand (SCF) in human multiple myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Interleukin-21 is a growth and survival factor for human myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Role of INTERLEUKIN-6 in the pathogenesis of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

The role of interleukin-1 beta in the pathogenesis of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Interleukin-6 activates phosphoinositol-3' kinase in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Signaling through a novel domain of gp130 mediates cell proliferation and activation of Hck and Erk kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Critical role for hematopoietic cell kinase (Hck)-mediated phosphorylation of Gab1 and Gab2 docking proteins in interleukin 6-induced proliferation and survival of multiple myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

STAT3 is required for the gp130-mediated full activation of the c-myc gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Lipid rafts and signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Plasma cell differentiation requires the transcription factor XBP-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I in myeloma cells that highly express IL-6 receptor α

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Insulin-like growth factor I induces migration and invasion of human multiple myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Translocation of Ku86/Ku70 to the multiple myeloma cell membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

WNT and beta-catenin signalling: diseases and therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Illegitimate WNT signaling promotes proliferation of multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Expression of high-mobility-group-protein HMGI-C mRNA in the peripheral blood is an independent poor prognostic indicator for survival in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Evidence of a role for RANKL in the development of myeloma bone disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

CD27-triggering on primary plasma cell leukaemia cells has anti-apoptotic effects involving mitogen activated protein kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Cell death: the significance of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Molecular determinants of the caspase-promoting activity of Smac/DIABLO and its role in the death receptor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Structural basis of IAP recognition by Smac/DIABLO

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) promotes mitochondrial dysfunction and apoptosis induced by 7-hydroxystaurosporine and mitogen-activated protein kinase kinase inhibitors in human leukemia cells that ectopically expres

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

NF-kappa B as a therapeutic target in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

The evolution of thalidomide and its IMiD derivatives as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Proteasome inhibitors disrupt the unfolded protein response in myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

The triterpenoid CDDO induces apoptosis in refractory CLL B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

The novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) potently enhances apoptosis induced by tumor necrosis factor in human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Effect of farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Identification of TOR signaling complexes: more TORC for the cell growth engine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Evidence that cyclin D1 mediates both growth and proliferation downstream of TOR in hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Downstream effectors of oncogenic ras in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

The 5TMM series: a useful in vivo mouse model of human multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Cytogenetic Abnormalities Correlate with the Plasma Cell Labeling Index and Extent of Bone Marrow Involvement in Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Synergistic induction of growth arrest and apoptosis of human myeloma cells by the IL-6 super-antagonist Sant7 and Dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.2.359

21 January 2018

Identifiers

DOI

10.1517/14728222.9.2.359

1 reference

release_6wxkitxrinfj5bhgqqv3w7nbq4

12 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6wxkitxrinfj5bhgqqv3w7nbq4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference